Annabel Samimy
Stock Analyst at Stifel
(4.59)
# 213
Out of 5,246 analysts
54
Total ratings
54.9%
Success rate
41.23%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Annabel Samimy
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EPRX Eupraxia Pharmaceuticals | Initiates: Buy | $25 | $7.10 | +252.11% | 1 | May 21, 2026 | |
| OCS Oculis Holding AG | Maintains: Buy | $40 → $50 | $29.49 | +69.55% | 3 | Mar 5, 2026 | |
| EOLS Evolus | Maintains: Buy | $20 → $17 | $6.09 | +179.15% | 2 | Jan 13, 2026 | |
| TRVI Trevi Therapeutics | Maintains: Buy | $15 → $18 | $14.13 | +27.39% | 1 | Dec 19, 2025 | |
| SUPN Supernus Pharmaceuticals | Maintains: Hold | $50 → $55 | $48.21 | +14.08% | 8 | Dec 19, 2025 | |
| RGNX REGENXBIO | Maintains: Buy | $40 → $45 | $6.35 | +608.66% | 3 | Dec 19, 2025 | |
| MLYS Mineralys Therapeutics | Maintains: Buy | $45 → $52 | $29.85 | +74.20% | 2 | Dec 19, 2025 | |
| MBX MBX Biosciences | Maintains: Buy | $45 → $50 | $31.85 | +56.99% | 2 | Dec 19, 2025 | |
| LGND Ligand Pharmaceuticals | Maintains: Buy | $220 → $230 | $229.33 | +0.29% | 2 | Dec 10, 2025 | |
| GPCR Structure Therapeutics | Maintains: Buy | $50 → $90 | $39.19 | +129.65% | 2 | Dec 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $87 → $145 | $113.99 | +27.20% | 3 | Nov 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $2.90 | +520.69% | 1 | Jan 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $17 | $5.07 | +235.31% | 4 | Nov 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $7.83 | +129.89% | 1 | Jul 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $24 | $11.33 | +111.83% | 1 | May 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $80 | $30.89 | +158.98% | 6 | Mar 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $225 → $230 | $239.83 | -4.10% | 8 | Mar 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $24 | $1.07 | +2,142.99% | 1 | Aug 24, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $700 → $750 | $2.12 | +35,277.36% | 3 | Apr 16, 2020 |
Eupraxia Pharmaceuticals
May 21, 2026
Initiates: Buy
Price Target: $25
Current: $7.10
Upside: +252.11%
Oculis Holding AG
Mar 5, 2026
Maintains: Buy
Price Target: $40 → $50
Current: $29.49
Upside: +69.55%
Evolus
Jan 13, 2026
Maintains: Buy
Price Target: $20 → $17
Current: $6.09
Upside: +179.15%
Trevi Therapeutics
Dec 19, 2025
Maintains: Buy
Price Target: $15 → $18
Current: $14.13
Upside: +27.39%
Supernus Pharmaceuticals
Dec 19, 2025
Maintains: Hold
Price Target: $50 → $55
Current: $48.21
Upside: +14.08%
REGENXBIO
Dec 19, 2025
Maintains: Buy
Price Target: $40 → $45
Current: $6.35
Upside: +608.66%
Mineralys Therapeutics
Dec 19, 2025
Maintains: Buy
Price Target: $45 → $52
Current: $29.85
Upside: +74.20%
MBX Biosciences
Dec 19, 2025
Maintains: Buy
Price Target: $45 → $50
Current: $31.85
Upside: +56.99%
Ligand Pharmaceuticals
Dec 10, 2025
Maintains: Buy
Price Target: $220 → $230
Current: $229.33
Upside: +0.29%
Structure Therapeutics
Dec 9, 2025
Maintains: Buy
Price Target: $50 → $90
Current: $39.19
Upside: +129.65%
Nov 24, 2025
Maintains: Buy
Price Target: $87 → $145
Current: $113.99
Upside: +27.20%
Jan 8, 2025
Initiates: Buy
Price Target: $18
Current: $2.90
Upside: +520.69%
Nov 22, 2024
Maintains: Buy
Price Target: $20 → $17
Current: $5.07
Upside: +235.31%
Jul 3, 2024
Initiates: Buy
Price Target: $18
Current: $7.83
Upside: +129.89%
May 3, 2024
Initiates: Buy
Price Target: $24
Current: $11.33
Upside: +111.83%
Mar 15, 2024
Reiterates: Buy
Price Target: $80
Current: $30.89
Upside: +158.98%
Mar 15, 2024
Maintains: Buy
Price Target: $225 → $230
Current: $239.83
Upside: -4.10%
Aug 24, 2021
Initiates: Buy
Price Target: $24
Current: $1.07
Upside: +2,142.99%
Apr 16, 2020
Maintains: Buy
Price Target: $700 → $750
Current: $2.12
Upside: +35,277.36%